PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects

About this update from Prf Technologies Ltd.

[{"type":"text","content":"New formulations designed to enhance postoperative recovery\nTEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (\"PainReform\" or the \"Company\"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. These novel formulations may incorporate both the analgesic and an anti-inflammatory agent, designed to enhance postoperative recovery. Nerve blockades are critical for managing pain over extended periods, preventing complications, and accelerating recovery post-surgery. Adding an anti-inflammatory agent, such as a steroid, to a local anesthetic like ropivacaine has been demonstrated to extend and enhance the anesthetic effect. This combination not only provides a quicker onset of pain relief but also reduces the reliance on opioids post-operatively. Ropivacaine is preferred over bupivacaine for surgical blocks due to its lower neurotoxicity and cardiotoxicity, as well as a reduced risk of bone chondrotoxicity. By combining ropivacaine with dexamethasone, a potent anti-inflammatory agent, PainReform aims to deliver superior pain management. This combination is already employed in various peripheral nerve blocks, including transversus abdominis plane blocks, interscalene blocks, and adductor canal blocks. PainReform's PRF-110 formulation uniquely supports the administration of ropivacaine-steroid mixtures while ensuring product stability—a challenging feat with such combinations. The company holds a patent for the ropivacaine and dexamethasone mixture and has successfully manufactured specific combination products of PRF-110, containing 3.6% or 3.0% ropivacaine and 0.1-0.5% dexamethasone. These formulations have demonstrated promising stability in ongoing studies. \"Long-acting mixtures of local anesthetics and anti-inflammatory agents are extensively used in nerve blocks, orthopedics, and other medical fields to provide symptomatic relief,\" said Ehud Geller, Chairman and interim Chief Executive Officer of PainReform. \"The unique properties of PRF-110, including its long-acting nature, viscosity, and safety, position it well for combination with anti-inflammatory agents to further enhance outcomes in po...

More updates from Prf Technologies Ltd.